Avalon GloboCare

Historical price data

Avalon GloboCare is a commercial-stage biotech focused on precision diagnostics and cell therapy, with a mission to bridge research and commercialization. Its core assets include the FDA-cleared KetoAir™ breathalyzer for metabolic monitoring and the QTY Code protein design platform developed with MIT. The company's strategy involves leveraging these platforms while diversifying into AI-driven media technology, though this creates a bifurcated focus between healthcare and tech.

Proprietary platforms include the FDA-registered KetoAir™ breathalyzer for ketosis monitoring and the QTY Code protein design platform (with MIT) for creating water-soluble cytokine receptors.

Faces intense competition in all segments: from wellness device makers in diagnostics, from well-funded biotechs in protein engineering, and from large tech firms in AI content creation. Its small size and limited capital are significant disadvantages.